A 42-year-old woman with bipolar I disorder has been on risperidone 6 mg daily for 2 years with good symptom control. She presents with amenorrhea for 4 months, galactorrhea, and decreased libido. Laboratory investigations show: prolactin 85 ng/mL (normal <25 ng/mL), TSH 2.1 mIU/L (normal), and free T4 10.2 pmol/L (normal). Pregnancy test is negative. What is the mechanism of this adverse effect?

Explanation

## Mechanism of Antipsychotic-Induced Hyperprolactinemia This patient has **antipsychotic-induced hyperprolactinemia**, a common endocrine side effect caused by dopamine D~2~ receptor antagonism in the tuberoinfundibular pathway. ### Dopamine's Physiological Role in Prolactin Regulation **Key Point:** Dopamine is the primary physiological inhibitor of prolactin secretion. It is released by hypothalamic neurons into the hypophyseal portal blood and acts on D~2~ receptors on lactotroph cells to suppress prolactin release. ### Mechanism of Antipsychotic-Induced Hyperprolactinemia ```mermaid flowchart TD A[Antipsychotic Administration]:::action --> B[Dopamine D2 Receptor Blockade<br/>in Tuberoinfundibular Pathway]:::action B --> C[Decreased Dopamine Inhibition<br/>of Lactotroph Cells]:::action C --> D[Disinhibition of Prolactin Secretion]:::action D --> E[Elevated Serum Prolactin<br/>Hyperprolactinemia]:::outcome E --> F{Clinical Consequences}:::decision F -->|In Women| G[Amenorrhea<br/>Galactorrhea<br/>Decreased Libido<br/>Gynecomastia]:::outcome F -->|In Men| H[Erectile Dysfunction<br/>Decreased Libido<br/>Gynecomastia<br/>Infertility]:::outcome ``` ### Relative Risk of Hyperprolactinemia by Antipsychotic | Antipsychotic Class | Risk Level | Mechanism | |-------------------|-----------|----------| | **Typical (1st-gen)** | Very High | High D~2~ affinity, poor BBB selectivity | | Risperidone | High | High D~2~ affinity, crosses BBB readily | | Paliperidone | High | Active metabolite of risperidone | | Amisulpride | High | Selective D~2~/D~3~ antagonist | | Olanzapine | Moderate | Lower D~2~ affinity, faster dissociation | | Quetiapine | Low | Rapid D~2~ dissociation | | Aripiprazole | Very Low | D~2~ partial agonist (stabilizes dopamine) | | Clozapine | Very Low | Weak D~2~ binding, rapid dissociation | **High-Yield:** Risperidone and paliperidone carry the highest risk among atypical antipsychotics due to their potent and sustained D~2~ blockade. ### Clinical Manifestations of Hyperprolactinemia **In Women:** - Amenorrhea or oligomenorrhea - Galactorrhea - Decreased libido and sexual dysfunction - Gynecomastia (less common) - Infertility **In Men:** - Erectile dysfunction - Decreased libido - Gynecomastia - Infertility (oligospermia) **Long-term Consequences:** - Osteoporosis (due to hypogonadism from prolactin-induced dopamine suppression in GnRH neurons) - Increased breast cancer risk (controversial but monitored) ### Differential Diagnosis of Hyperprolactinemia **Key Point:** Always exclude other causes before attributing hyperprolactinemia solely to antipsychotics: 1. **Hypothyroidism** — elevated TRH stimulates prolactin (TSH and free T4 normal here) 2. **Pituitary adenoma** — prolactin typically >200 ng/mL; MRI brain indicated 3. **Pregnancy** — ruled out by negative pregnancy test 4. **Renal failure** — decreased prolactin clearance 5. **Chest wall irritation** — herpes zoster, breast stimulation 6. **Medications** — metoclopramide, domperidone, SSRIs, venlafaxine, tricyclics ### Management Strategy ```mermaid flowchart TD A[Antipsychotic-Induced Hyperprolactinemia]:::outcome --> B{Severity & Symptom Burden?}:::decision B -->|Mild, Asymptomatic| C[Continue current antipsychotic<br/>Monitor prolactin annually]:::action B -->|Symptomatic| D[Switch to low-prolactin agent:<br/>aripiprazole, quetiapine, clozapine]:::action D --> E{Response?}:::decision E -->|Yes| F[Continue new antipsychotic]:::outcome E -->|No| G[Add dopamine agonist:<br/>bromocriptine or cabergoline]:::action G --> H[Monitor for psychiatric relapse<br/>and prolactin normalization]:::action ``` **Clinical Pearl:** Switching to aripiprazole (a D~2~ partial agonist) is often the most effective strategy because it maintains dopaminergic tone in the tuberoinfundibular pathway while preserving antipsychotic efficacy in mesolimbic/mesocortical pathways. **Warning:** Dopamine agonists (bromocriptine, cabergoline) can precipitate psychotic relapse in patients with schizophrenia and should be used cautiously and only if antipsychotic switching is not feasible.